|
|
|
| Analysis of the Efficacy and Impact of Renin-Angiotensin System Inhibitors Combined with Hydroxychloroquine in the Treatment of IgA Nephropathy and Nephroprotective Effects |
| WU Qimei, XU Xingxin, LU Wen |
| The First Affiliated Hospital of Anhui Medical University, Anhui Hefei 230000, China |
|
|
|
|
Abstract Objective: To investigate the efficacy and renal protective effect of renin angiotensin system inhibitor (RASI) combined with hydroxychloroquine in the treatment of IgA nephropathy. Methods: The study subjects were 84 patients with IgA nephropathy admitted from January 2018 to December 2022. According to the random number table method, the study subjects were divided into the control group (42 cases) and the observation group (42 cases). The patients in the control group took RASI, and the observation group took hydroxychloroquine sulfate tablets on the basis of the control group for 3 months. The clinical effects of the two groups were compared. The renal function indicators and treatment safety of the two groups of patients before and after treatment were compared. Results: The difference in serum 24-UPro content between the observation group after treatment and before treatment was significantly greater than that of the control group (P<0.05). After treatment, the levels of 24-USPro in both groups were lower than before treatment (P<0.05), and the levels of Scr were higher than before treatment (P<0.05).There was no statistically significant difference in serum Scr level and UA level between the observation group after treatment and before treatment (P>0.05); there was no statistically significant difference in the incidence of adverse reactions between the two groups of patients (P>0.05). Conclusion: The combination of renin-angiotensin system inhibitor and hydroxychloroquine has a good effect on patients with IgA nephropathy, helping to control proteinuria, protect the kidney and maintain the stability of renal function.
|
|
|
|
|
|
[1] 丁苗慧,张颖,李远,等.P因子介导的C5a/C5aR轴活化在IgA肾病肾脏足细胞损伤中的作用[J].郑州大学学报(医学版),2023,58(1):82-88.
[2] 洪琴,王娅,粟凤,等.不同病理分级IgA肾病患者肾小球足细胞自噬体数目分析[J].贵州医科大学学报,2022,47(11):1288-1293,1299.
[3] 张芮,林燕.曹式丽教授从外感辨治IgA肾病经验[J].西部中医药,2021,34(2):52-55.
[4] 李婷婷,石磊.T细胞在IgA肾病发病机制中的作用[J].河北医学,2020,26(2):346-349.
[5] 彭露婷,黄志荣,官慧儿,等.羟氯喹补充治疗IgA肾病安全性和有效性的系统评价[J].中国医院药学杂志,2022,42(14):1463-1468.
[6] 中华医学会.临床诊疗指南·肾脏病学分册[M].北京:人民卫生出版社,2011.35-39.
[7] Cattran DC,Coppo R,Cook HT,et al.The Oxford classification of IgA nephropathy:rationale,clinicopathological correlations,and classification[J].Kidney Int,2009,76(5):534-545.
[8] Floege J,Barbour S J,Cattran D C,et al.Management and treatment of glomerular diseases (part 1):conclusions from a kidney disease:improving global outcomes (KDIGO) controversies conference[J].Kidney Int,2019,95(2):268-80.
[9] 魏凯悦,米焱.羟氯喹治疗IgA肾病的研究进展[J].肾脏病与透析肾移植杂志,2022,31(3):266-270.
[10] 潘怡璇,陈肖蓉,任萍萍,等.羟氯喹治疗IgA肾病疗效与安全性的单中心回顾性分析[J].中华肾脏病杂志,2022,38(2):81-90.
[11] 丘昭文,吴勐,邓金秀,等.羟氯喹联合肾素-血管紧张素系统抑制剂(RASI)对IgA肾病减少蛋白尿的回顾性研究[J].中国医药指南,2022,20(36):79-81.
[12] Fanouriakis A,Kostopoulou M,Alunno A,et al.2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J].Ann Rheum Dis,2019,78(6):736-45. |
|
|
|
2023, Vol. 29 
